Information on the association of erlotinib (Tarceva®) with gastrointestinal perforation, Stevens-Johnson syndrome and corneal perforation or ulceration [Roche]

Roche updates healthcare professionals on the increased risk of developing gastrointestinal perforations in patients receiving erlotinib (Tarceva®). Additionally, there have also been very rare occurrences of bullous, blistering and exfoliative skin conditions suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis as well as corneal perforation or ulceration in patients receiving Tarceva®. Tarceva® treatment should be discontinued in patients who develop gastrointestinal perforation, severe bullous, blistering or exfoliative skin conditions or acute/worsening ocular disorders such as eye pain.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.